Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Blood

Volumn 112, Issue 7, 2008, Pages 2687-2693

  Geisler, Christian H ^a,b,k   Kolstad, Arne ^a,c   Laurell, Anna ^a,d   Andersen, Niels S ^a,b   Pedersen, Lone B ^a,b   Jerkeman, Mats ^a,e   Eriksson, Mikael ^a,e   Nordström, Marie ^a,f   Kimby, Eva ^a,f   Boesen, Anne Marie ^a,g   Kuittinen, Outi ^a,h   Lauritzsen, Grete F ^a,c   Nilsson Ehle, Herman ^a,i   Ralfkiær, Elisabeth ^a,b   Åkerman, Måns ^a,e   Ehinger, Mats ^a,e   Sundström, Christer ^a,d   Langholm, Ruth ^a,c   Delabie, Jan ^a,c   Karjalainen Lindsberg, Marja Liisa ^a,j   Brown, Peter ^a,b   Elonen, Erkki ^a,j   more..

^a Nordic Lymphoma Group   (Denmark)

^b Norwegian Radium Hospital ^*

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h OULU UNIVERSITY HOSPITAL   (Finland)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY OF HELSINKI   (Finland)

^k Rigshospitalet   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; IMMUNOTHERAPY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STEM CELL TRANSPLANTATION; BONE MARROW PURGING; CYTOLOGY; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PHASE 2 CLINICAL TRIAL; STEM CELL; TIME; TREATMENT OUTCOME;

ADULT; AGED; BONE MARROW PURGING; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; KI-67 ANTIGEN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; STEM CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 53449089095     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-147025     Document Type: Article

References (37)

1. Fisher Rl, Dahlberg S, Nathwani BN, et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995;85:1075-1082.
2. Weisenburger DD, Vose JM. Greiner TC, et al. Mantle cell lymphoma: a clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol. 2000;64:190-196.
3. Hiddemann W, Unterhalt M, Herrmann Ft, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998;16:1922-1930.
4. Andersen NS, Jensen MK, de Nully Brown P, et al. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer. 2002;38:401-408.
5. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs event-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677-2684.
6. Andersen NS, Pedersen L, Elonen E, et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol. 2003;71:73-80.
7. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose metothrexate/cytarabine followed by stem cell transplantation: an active regimen for mantle cell lymphoma. J Clin Oncol. 1998;16:3803-3809.
8. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood. 2000;96:864-869.
9. Swerdlow SH, Berger F, Isaacson PI, et al. Mantle cell lymphoma, In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology & Genetics: Tumours of Haematopoietic and Lymphoid Tissues Lyon, France: IARC Press; 2001:168-170.
10. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
11. Andersen NS, Donovan JW, Zuckerman A et al. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. Exp Hematol. 2002;30:703-710.
12. Andersen NS, Pedersen LB. Laurell A et al. Successful preemptive treatment of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma [abstract]. Blood. 2007; 110:386a. Abstract 1281.
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1253.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53:457-481.
15. Weisenburger DD, Armitage JO. Mantle cell lymphoma: an entity comes of age. Blood. 1996;87: 4483-4494.
16. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984-1992.
17. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of eventfree survival. J Clin Oncol. 2002;20:1288-1294.
18. Cortelazzo S, Magni M, Tarella C, et al. Update of a GITIL Cohort Study: frontline high dose sequential chemotherapy with rituximab and autologous stem cell transplantation induces a high rate of long-term remissions in patients with mantle cell lymphoma [abstract]. Blood. 2007;110:386a. Abstract 1282.
19. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following highdose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003;102:749-755.
20. Khouri IF, Saliba RM, Okoroji GJ, Acholonu SA, Champlin RE. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer. 2003;98:2630-2635.
21. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23:7013-7023.
22. Epner EM, Unger J, Miller T, et al. A multicenter trial of hyperCVAD+rituxan in patients with newly diagnosed mantle cell lymphoma [abstract]. Blood. 2007;110:121a. Abstract 387.
23. Dreyling M, Hoster E, Hermine O, et al. European MCL Network: an update on current first line trials [abstract]. Blood. 2007;110:121a. Abstract 388.
24. Ladetto M, Magni M, Pagliano G, et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant. 2006;12: 1270-1276.
25. Forstpointner R, Unterhalt M, Dreyling M, etal. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003-4008.
26. Milpied N, Gaillard F, Moreau P, et al. High-dose therapy with stem-cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant. 1998;22:645-650.
27. Dreger P, Rieger M, Seyfarth B, et al. Rituximabaugmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica. 2007;92:42-49.
28. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185-197.
29. Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood. 2006;107:3407.
30. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131:29-38.
31. Räty R, Franssila K, Joensuu H, et al. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol. 2002; 69:11-20.
32. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111: 2385-2387.
33. Dreger P, Laport GG. Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2008;14:100-107.
34. Tarn CS, Ledesma C, Korbling M, et al. Nonmyeloablative allogeneic stem cell transplantation (NMT) overcomes the adverse effects of treatment resistance and high beta-2-microglobulin in patients with mantle cell lymphoma (MCL): an analysis of 123 transplantations at the MD Anderson Cancer Center [abstract]. Blood. 2007;110:149a. Abstract 484.
35. Andersen NS, Donovan JW, Borus JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood. 1997;90:4212-4221.
36. Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after highdose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood. 2006;107:2271-2278.
37. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706-714.